Andrew Allen, M.D., Ph.D. President and Chief Executive Officer Gritstone Oncology, Inc. 5858 Horton Street, Suite 210 Emeryville, CA 94608

may better understand your disclosure.

Re: Gritstone Oncology, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted July 9, 2018 CIK No. 0001656634

Dear Dr. Allen:

We have reviewed your amended draft registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we

Please respond to this letter by providing the requested information and either submitting

an amended draft registration statement or publicly filing your registration statement on

EDGAR. If you do not believe our comments apply to your facts and circumstances or do not

believe an amendment is appropriate, please tell us why in your response.

After reviewing the information you provide in response to these comments and your amended draft registration statement or filed registration statement, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our June 3, 2018 letter.

Amendment No. 1 to Draft Registration Statement on Form S-1

License Agreement with Arbutus Biopharma Corporation, page 121

We note your revised disclosure in response to prior comment 5. Please 1. expand to

indicate when the last-to-expire patent is currently scheduled to expire.

Andrew Allen, M.D., Ph.D. Gritstone Oncology, Inc.

July 18, 2018

Page 2

You may contact Rolf Sundwall at 202-551-3105 or Jim B. Rosenberg at 202-551-3679 if you have questions regarding comments on the financial statements and related matters. Please contact Ada D. Sarmento at 202-551-3798 or Mary Beth Breslin at 202-551-3625 with any other questions.

FirstName LastNameAndrew Allen, M.D., Ph.D.

Division of

Corporation Finance Comapany NameGritstone Oncology, Inc.

Office of Healthcare &

Insurance July 18, 2018 Page 2 cc: Brian J. Cuneo, Esq. FirstName LastName